Neumora Therapeutics has been given 180 days to bring its share price back above Nasdaq’s minimum bid requirement. The company received notice on October 26 that its stock was trading below $1 per share, putting its continued listing on the Nasdaq Global Select Market at risk.
The notice does not mean the shares are being delisted now. Neumora has until April 26, 2027, to meet the requirement, and says it is considering options that include a reverse stock split.
- To regain compliance, Neumora’s closing bid price must be at least $1 for 10 consecutive business days by April 26, 2027.
- If it does not meet that deadline, the company may be eligible for an additional compliance period. That would require applying to transfer its listing to the Nasdaq Capital Market and meeting that market’s other initial listing standards, as well as paying an application fee and notifying Nasdaq of its intent to address the share-price shortfall.
- If Neumora fails to regain compliance during the available period, Nasdaq could move to delist the stock. The company would have the right to appeal, but there is no assurance an appeal would succeed.
- Neumora plans to monitor its share price and consider ways to address the shortfall, including a reverse stock split. It has not announced that it will undertake one.
What changes for investors: Neumora’s listing is not being removed immediately, but the company faces a deadline to satisfy Nasdaq’s minimum-price rule. A reverse split is among the options under consideration, not a decision already made.